Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06124378 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Nov 16, 2022 to Nov 13, 2023v5 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Oct 11, 2024 to Feb 28, 2025
    • Study completion date: Oct 31, 2027 to Nov 30, 2026
    • Site details revised
  2. Primary completion date changed from estimate of Nov 30, 2026 to Oct 11, 2024
    • Study completion date: Nov 30, 2026 to Oct 31, 2027
    • Start date: Nov 13, 2023 to Nov 16, 2022
    • Eligibility criteria revised
    v4
  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Start date: Dec 1, 2023 to Nov 13, 2023
    • Interventions: Anti-PD-1 monoclonal antibody (Drug), Capecitabine 500 MG (Drug), Colectomy (Procedure), Oxaliplatin (Drug) to Capecitabine (Drug), Colectomy (Procedure), Oxaliplatin (Drug), Tislelizumab (Drug)
    • Secondary endpoints revised (8)
    • Study description expanded, about 7 words
    • Site details revised
    • Eligibility criteria expanded, about 5 words
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced Microsatellite Stable (MSS) colon cancer.
Trial Details
NCT Number NCT06124378
Lead Sponsor First Affiliated Hospital of Guangxi Medical University
Conditions
(from sponsor)		 Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
Related terms Colonic Neoplasms
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov